Developer docs
API playgroundTry for free, no card

Search company profiles

Viewmind

Full company profile

uuid0002rfz

Namestring
Viewmind
Websiteurl
viewmind.ai
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Viewmind is a digital health and artificial intelligence company developing digital biomarkers for the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). Founded in 2016 and headquartered in Alpine, United States, the company is also identified as a Latin America-based AI startup, having been featured in Hi Ventures' AI 100 Early Stage Map 2025. Its core offering is an AI-driven cognitive assessment that detects neurodegenerative conditions at earlier stages than traditional diagnostic methods, positioning it at the intersection of AI-native diagnostics and the high-burden Alzheimer's care market. Target end users are not explicitly disclosed but likely include healthcare providers, neurology clinics, clinical researchers, and pharmaceutical companies engaged in Alzheimer's drug development and patient screening.

The company's product is built around proprietary AI models that analyze digital biomarker data to identify signatures of cognitive decline. As an AI-native diagnostic, the underlying technology constitutes the company's primary value proposition rather than serving as an add-on feature. Headcount remains small (1-10 employees), and no patents, regulatory clearances, or third-party clinical validation milestones are disclosed in available sources, leaving the depth of the AI capability largely self-asserted.

Viewmind's business model is not publicly disclosed. It has raised between $1M and $10M USD across multiple funding rounds between 2020 and 2023 (with only the 2020 Cites-led $1M round publicly confirmed), and recently hired its first dedicated commercial leader (VP of Sales & Business Development). The company appears to be in a pre-commercial or early-commercial phase, with revenue figures undisclosed and its public website showing only a verification page. The GTM motion and pricing model are therefore not yet observable.

Short descriptiontext

Viewmind is a digital health and AI company developing digital biomarkers for early detection of Alzheimer's disease and Mild Cognitive Impairment, serving healthcare providers, researchers, and pharma with AI-native cognitive assessment technology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
digital health diagnostics, Alzheimer's disease detection, cognitive health assessment, AI medical biomarkers, neurological screening software
Industry4 codes
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Software Publishers5132
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Digital Health Cognitive Diagnostics
No data
Cost components3 values
Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Viewmind develops and sells a digital biomarker that uses artificial intelligence to enable early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). The offering is a non-invasive cognitive screening software tool aimed at clinicians and clinical researchers seeking earlier identification of cognitive decline.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Viewmind Digital Biomarker for Alzheimer's and MCI Detection
CategoryDigital Health Cognitive Diagnostics
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Viewmind

Digital Health Cognitive Diagnosticsviewmind.ai

Viewmind is a digital health and AI company developing digital biomarkers for early detection of Alzheimer's disease and Mild Cognitive Impairment, serving healthcare providers, researchers, and pharma with AI-native cognitive assessment technology.

What Viewmind does

Viewmind is a digital health and artificial intelligence company developing digital biomarkers for the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). Founded in 2016 and headquartered in Alpine, United States, the company is also identified as a Latin America-based AI startup, having been featured in Hi Ventures' AI 100 Early Stage Map 2025. Its core offering is an AI-driven cognitive assessment that detects neurodegenerative conditions at earlier stages than traditional diagnostic methods, positioning it at the intersection of AI-native diagnostics and the high-burden Alzheimer's care market. Target end users are not explicitly disclosed but likely include healthcare providers, neurology clinics, clinical researchers, and pharmaceutical companies engaged in Alzheimer's drug development and patient screening.

The company's product is built around proprietary AI models that analyze digital biomarker data to identify signatures of cognitive decline. As an AI-native diagnostic, the underlying technology constitutes the company's primary value proposition rather than serving as an add-on feature. Headcount remains small (1-10 employees), and no patents, regulatory clearances, or third-party clinical validation milestones are disclosed in available sources, leaving the depth of the AI capability largely self-asserted.

Viewmind's business model is not publicly disclosed. It has raised between $1M and $10M USD across multiple funding rounds between 2020 and 2023 (with only the 2020 Cites-led $1M round publicly confirmed), and recently hired its first dedicated commercial leader (VP of Sales & Business Development). The company appears to be in a pre-commercial or early-commercial phase, with revenue figures undisclosed and its public website showing only a verification page. The GTM motion and pricing model are therefore not yet observable.

Viewmind firmographics

Firmographics
Name
Viewmind
Website
https://viewmind.ai
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Viewmind is a digital health and AI company developing digital biomarkers for early detection of Alzheimer's disease and Mild Cognitive Impairment, serving healthcare providers, researchers, and pharma with AI-native cognitive assessment technology.
Ownership category
akta.pro rank

Viewmind industry classification

Industry
Product category
Digital Health Cognitive Diagnostics
NAICS
Software Publishers (5132), Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Digital health diagnostics
  • Alzheimer's disease detection
  • Cognitive health assessment
  • AI medical biomarkers
  • Neurological screening software

Where Viewmind is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Viewmind business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales

Viewmind product offering

Product offering

Core offering

Viewmind develops and sells a digital biomarker that uses artificial intelligence to enable early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). The offering is a non-invasive cognitive screening software tool aimed at clinicians and clinical researchers seeking earlier identification of cognitive decline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Viewmind Digital Biomarker for Alzheimer's and MCI Detection

Companies that use Viewmind

Customer profile

Ideal customer profiles1 record

Viewmind technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Viewmind partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights4 records

Viewmind competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Viewmind financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Viewmind leadership team

Management profile

Number of profiles

Profiles4 records

Viewmind funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Viewmind M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viewmind

What does Viewmind do?

Viewmind develops and sells a digital biomarker that uses artificial intelligence to enable early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). The offering is a non-invasive cognitive screening software tool aimed at clinicians and clinical researchers seeking earlier identification of cognitive decline.

Is Viewmind a public or private company?

Viewmind is a private company. It is classified as venture growth investor backed and is currently operating.

When was Viewmind founded?

Viewmind was founded in 2016. It employs 11 to 50 people.

Where is Viewmind based?

Viewmind is headquartered in New York, United States, in the North America region.

Does Viewmind have an API?

No public API is recorded for Viewmind.

What industry is Viewmind in?

Viewmind's product category is Digital Health Cognitive Diagnostics. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping SolutionFrost & Sullivan awarded ViewMind the 2024 North American Technology Innovation Leadership Award for its ocular digital phenotyping solution. The non-invasive, language-free test measures eye movements to assess brain health, aiding drug development and patient care. The company aims to revolutionize central nervous system drug development and precision patient care.PR NewswireViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping SolutionFrost & Sullivan recognized ViewMind with the 2024 North American Technology Innovation Leadership Award for its ocular digital phenotyping solution that assesses brain and cognitive health through eye movement analysis. The patented technology uses a head-mounted display with sensors to track eye movements in response to visual stimuli, providing non-invasive, language-free cognitive assessments with applications in pharmaceutical drug development and healthcare monitoring. The award highlights ViewMind's contribution to precision brain health diagnostics and central nervous system drug development.ViewmindPharmaceutical Solutions: ViewMind's InnovationsViewMind has developed technology to enhance clinical trial screening accuracy and patient monitoring, especially for CNS drugs and Alzheimer's research. The company's solutions aim to reduce costs, increase trial success rates, and improve patient outcomes by providing rapid, non-invasive assessments.PR NewswireViewMind today announces the appointment of Denise Kelly as Vice President Sales & Business Development.ViewMind announced the appointment of Denise Kelly as Vice President Sales and Business Development, bringing over 25 years of commercial experience, primarily from Medtronic where she managed over $300 million in sales for neuromodulation, spine implants, and navigation and robotic solutions. The appointment is part of ViewMind's strategy to scale and expand globally with its digital biomarker technology for cognitive health diagnosis. Denise will lead ViewMind's global commercial rollout targeting physicians and patients across the healthcare continuum.BioSpaceViewMind announces developer agreement with HP to help revolutionise the diagnosis and treatment of cognitive disordersViewMind announced a developer agreement with HP to use the Reverb G2 Omnicept VR headset for diagnosing and monitoring cognitive disorders. The headset's biosensors track eye movements, feeding data to ViewMind's AI algorithms for screening and monitoring. The collaboration aims to expand global distribution of ViewMind's digital biomarker technology.PR NewswireViewMind announces developer agreement with HP to help revolutionise the diagnosis and treatment of cognitive disordersViewMind announced a development agreement with HP Inc to integrate HP's Reverb G2 Omnicept VR Headset into ViewMind's medical device solution for diagnosing and monitoring cognitive disorders such as Alzheimer's disease. ViewMind will use the headset's biosensors to track eye movements in response to visual stimuli, sending biometric data to its AI algorithms for screening and diagnosis. The partnership is aimed at enabling ViewMind to rapidly scale and secure global distribution for its digital biomarker technology.PR NewswireViewMind Applauded by Frost & Sullivan for Its One-of-a-Kind Digital Biomarker Technology for Neurocognitive DisordersFrost & Sullivan recognized ViewMind with the 2021 Global Enabling Technology Leadership Award for its AI-powered digital biomarker technology that can detect neurocognitive disorders such as Alzheimer's up to 20 years before clinical symptoms appear. The technology uses augmented and virtual reality eye-tracking to collect over 10,000 datapoints per patient, correlating results with specific diseases including Alzheimer's, Parkinson's, multiple sclerosis, and stroke-related dementias. ViewMind operates across the United States, Europe, the Middle East, Latin America, and Asia, positioning the company for accelerated revenue growth as medical centers and elderly care facilities adopt its cognitive health assessment solutions.PR NewswireViewMind Inc Announces Appointment of Chief Executive OfficerViewMind Inc, a medical device, digital health and AI company, has appointed Mark Edwards as CEO with immediate effect, transitioning him from his role as Chairman and Co-founder since 2019. The company has pioneered digital biomarkers capable of diagnosing Alzheimer's up to 20 years before symptoms appear, and has also developed biomarkers for Parkinson's disease, multiple sclerosis, and Long COVID. The appointment coincides with the company scaling its operations amid growing global demand for cognitive health diagnostics, with the WHO projecting Alzheimer's cases will double every 20 years and care costs rising from $1 trillion in 2018 to an expected $2 trillion by 2030.